552 related articles for article (PubMed ID: 7958890)
1. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
2. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
3. Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc.
Thøger Andersen AS; Jensen AW; Grant P; Arulampalam V; Pettersson S; Junker S
Mol Immunol; 1997 Feb; 34(2):97-107. PubMed ID: 9188842
[TBL] [Abstract][Full Text] [Related]
4. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
5. The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes.
Madisen L; Krumm A; Hebbes TR; Groudine M
Mol Cell Biol; 1998 Nov; 18(11):6281-92. PubMed ID: 9774645
[TBL] [Abstract][Full Text] [Related]
6. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
7. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
Müller JR; Janz S; Potter M
Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
[TBL] [Abstract][Full Text] [Related]
8. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
9. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
10. Aberrant regulation of the IgH 3' enhancer by c-myc in plasmacytoma cells.
Arulampalam V; Grant P; Poellinger L; Pettersson S
Mol Immunol; 1995 Dec; 32(17-18):1369-75. PubMed ID: 8643106
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional deregulation of myc in IgH/myc 6;7 translocation carrying rat immunocytomas.
Axelson H; Pear WS; Panda CK; Bazin H; Klein G; Sümegi J
Genes Chromosomes Cancer; 1991 Mar; 3(2):142-8. PubMed ID: 1906344
[TBL] [Abstract][Full Text] [Related]
12. Illegitimate recombinations between c-myc and immunoglobulin loci are remodeled by deletions in mouse plasmacytomas but not in Burkitt's lymphomas.
Müller JR; Janz S; Potter M
Curr Top Microbiol Immunol; 1995; 194():425-9. PubMed ID: 7895518
[TBL] [Abstract][Full Text] [Related]
13. Genetic recombinations between c-myc and Igh mu as precursors for recombinations between c-myc and Igh alpha in BALB/c plasmacytomas.
Janz S; Kovalchuk AL; Müller JR; Potter M
Curr Top Microbiol Immunol; 1997; 224():241-50. PubMed ID: 9308247
[TBL] [Abstract][Full Text] [Related]
14. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
15. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
16. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
17. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
18. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
Hu HM; Kanda K; Zhang L; Boxer LM
Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
[TBL] [Abstract][Full Text] [Related]
19. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb.
Joos S; Falk MH; Lichter P; Haluska FG; Henglein B; Lenoir GM; Bornkamm GW
Hum Mol Genet; 1992 Nov; 1(8):625-32. PubMed ID: 1301171
[TBL] [Abstract][Full Text] [Related]
20. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.
Taub R; Kirsch I; Morton C; Lenoir G; Swan D; Tronick S; Aaronson S; Leder P
Proc Natl Acad Sci U S A; 1982 Dec; 79(24):7837-41. PubMed ID: 6818551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
